Longeveron
Biotechnology, 1951 Nw 7th Ave, Miami, Florida, 33136, United States, 11-50 Employees
Phone Number: 13*********
Who is LONGEVERON
We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Our lead investigational product is Lomecel-BTM, which is de...
Read More
-
Headquarters: 1951 Nw 7th Ave, Miami, Florida, 33136, United States
-
Date Founded: 2014
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Does something look wrong? Fix it. | View contact records from LONGEVERON
Longeveron Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Longeveron
Answer: Longeveron's headquarters are located at 1951 Nw 7th Ave, Miami, Florida, 33136, United States
Answer: Longeveron's phone number is 13*********
Answer: Longeveron's official website is https://longeveron.com
Answer: Longeveron's revenue is $5 Million to $10 Million
Answer: Longeveron's SIC: 2836
Answer: Longeveron's NAICS: 325414
Answer: Longeveron has 11-50 employees
Answer: Longeveron is in Biotechnology
Answer: Longeveron contact info: Phone number: 13********* Website: https://longeveron.com
Answer: We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Our lead investigational product is Lomecel-BTM, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging. We are currently conducting Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimers disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS), which is the current exception to our focus on aging. Our mission is to advance Lomecel-BTM and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Our philosophy is that healthy aging can be improved through regenerative medicine approaches. Life expectancy has substantially increased over the past century as a result of medical and public health advancements. However, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging a period known as healthspan. As we age, we experience a profound decline, in both number and function, in our own MSCs, a decrease in immune system function, decline in blood vessel functioning, chronic inflammation and other issues. Our clinical data suggest that Lomecel-BTM addresses these conditions through multiple mechanisms of action, or MOAs, that simultaneously target key aging-related processes.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month